Physician profile
Steven Ingram
NPI 1972145563
$2,002.05
in general payments reported to CMS, 2019-2025
16 companies · $961 in 2025
The $961 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $26.19 · 2023: $573 · 2024: $442 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $729.54 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $395.76 | 2023-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $215.78 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $160.78 | 2023-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.57 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $126.78 | 2022-2024 | Xarelto |
| Pfizer INC. | $42.52 | 2025 | |
| United Therapeutics Corporation | $42.28 | 2025 | Remodulin, Orenitram, Tyvaso |
| Edwards Lifesciences Corporation | $25.09 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Stryker Corporation | $24.58 | 2025 | Flowtriever |
| Alnylam Pharmaceuticals INC. | $19.34 | 2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $17.63 | 2025 | Camzyos |
| Bridgebio Pharma, INC. | $16.98 | 2025 | Attruby |
| Abbott Laboratories | $16.33 | 2025 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $15.18 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.91 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.